並列摘要
Statins, which are competitive inhibitor of HMGCoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase, reduce cholesterol blood levels. Because they can down regulate products of the mevalonate pathway. In addition to this main activity, statins show pleiotropic effects such as antitoxidant, induce apoptosis, anti-inflammatory, anti-angiogenenic, and anti-proliferative pro-perties. These seem to support the beneficial effect and the mechanism of statin use on cancer patients. Several studies demonstrated the persistent use of statins were associated with a lower ovarian cancer risk, and improved survival rate, but other studies reported no effect. Therefore, more studies are needed to clarify these controversial results.
延伸閱讀
- 李耀泰、陳福民、郭宗正（2022）。Statin用在子宮內膜癌的檢視。婦癌醫學期刊，(56)，1-5。https://www.airitilibrary.com/Article/Detail?DocID=P20150521002-202210-202211040005-202211040005-1-5
- 李耀泰、陳福民、侯廣瓊、鄭文雄、郭宗正（2008）。Docetaxel治療卵巢癌之檢視。中華民國婦癌醫學雜誌，(2008年1)，7-13。https://doi.org/10.7010/JGO.200804.0007
- 李耀泰、陳福民、郭宗正（2022）。Niraparib治療卵巢癌的檢視。婦癌醫學期刊，(55)，1-5。https://www.airitilibrary.com/Article/Detail?DocID=P20150521002-202204-202204290007-202204290007-1-5
- 李耀泰、陳福民、何民康、鄭文雄、郭宗正（2008）。Thalidomide治療卵巢癌的檢視。中華民國婦癌醫學雜誌，(2008年1)，38-43。https://doi.org/10.7010/JGO.200804.0038
- 李耀泰、陳福民、柯天龍、鄭文雄、郭宗正（2008）。Using Irinotecan in Patients with Epithelial Ovarian Cancer。中華民國婦癌醫學雜誌，(2008年1)，14-19。https://doi.org/10.7010/JGO.200804.0014